Quest Diagnostics Inc (DGX) : Aston Asset Management scooped up 1,347 additional shares in Quest Diagnostics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 10, 2016. The investment management firm now holds a total of 49,819 shares of Quest Diagnostics Inc which is valued at $3,783,753.Quest Diagnostics Inc makes up approximately 2.31% of Aston Asset Management’s portfolio.
Other Hedge Funds, Including , First Trust Advisors Lp reduced its stake in DGX by selling 185,541 shares or 22.58% in the most recent quarter. The Hedge Fund company now holds 636,037 shares of DGX which is valued at $48,307,010. Quest Diagnostics Inc makes up approx 0.16% of First Trust Advisors Lp’s portfolio.Global X Management Co boosted its stake in DGX in the latest quarter, The investment management firm added 1,804 additional shares and now holds a total of 2,039 shares of Quest Diagnostics Inc which is valued at $154,515. Quest Diagnostics Inc makes up approx 0.01% of Global X Management Co’s portfolio.Wedbush Securities Inc reduced its stake in DGX by selling 77 shares or 2.23% in the most recent quarter. The Hedge Fund company now holds 3,383 shares of DGX which is valued at $256,364. Quest Diagnostics Inc makes up approx 0.05% of Wedbush Securities Inc’s portfolio.Commerce Bank reduced its stake in DGX by selling 792 shares or 4.99% in the most recent quarter. The Hedge Fund company now holds 15,067 shares of DGX which is valued at $1,132,586. Quest Diagnostics Inc makes up approx 0.02% of Commerce Bank’s portfolio.
Quest Diagnostics Inc opened for trading at $76 and hit $76.825 on the upside on Monday, eventually ending the session at $76.8, with a gain of 1.12% or 0.85 points. The heightened volatility saw the trading volume jump to 9,23,599 shares. Company has a market cap of $10,864 M.
On the company’s financial health, Quest Diagnostics Inc reported $1.12 EPS for the quarter, based on the information available during the earnings call on Apr 21, 2016. Analyst had a consensus estimate of $1.12. The company had revenue of $1863.00 million for the quarter, compared to analysts expectations of $1823.36 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS.
Many Wall Street Analysts have commented on Quest Diagnostics Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 76 from a previous price target of $70 .Company shares were Reiterated by Barclays on Apr 22, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 75 from a previous price target of $72 .Company shares were Reiterated by Mizuho on Apr 21, 2016 to “Buy”, Firm has raised the Price Target to $ 84 from a previous price target of $75 .
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.